8-K: LENZ Therapeutics Stockholders Elect Directors, Ratify Auditor at 2025 Annual Meeting
Annual Meeting Results
LENZ Therapeutics, Inc. announced the successful election of Class III and Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 annual meeting of stockholders.
Summary
- LENZ Therapeutics, Inc. held its 2025 annual meeting of stockholders on June 10, 2025.
- As of the record date of April 14, 2025, there were 27,544,520 shares of common stock outstanding, with 17,983,676 shares represented at the meeting, either by proxy or in person.
- Kimberlee C. Drapkin and Zach Scheiner were elected as Class III directors, receiving 12,390,015 and 12,714,299 votes For, respectively, to serve until the Company's 2027 annual meeting.
- Frederic Guerard and James McCollum were elected as Class I directors, receiving 15,369,962 and 15,397,013 votes For, respectively, to serve until the Company's 2028 annual meeting.
- The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 17,979,770 votes For.
Sentiment
Score: 7
Explanation: The successful election of all proposed directors and the ratification of the independent auditor reflect stable corporate governance and shareholder alignment on these routine matters, which is generally a positive sign for operational stability.
Positives
- All nominated directors were successfully elected, ensuring board continuity and stability.
- The appointment of Ernst & Young LLP as the independent registered public accounting firm was overwhelmingly ratified, indicating strong shareholder support for the company's financial oversight.
Industry Context
This filing details routine corporate governance matters, specifically the outcomes of the annual stockholder meeting, and does not provide information related to broader industry trends or competitive positioning.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class III Director | NA | Kimberlee C. Drapkin | June 10, 2025 | Elected at annual meeting |
| Class III Director | NA | Zach Scheiner | June 10, 2025 | Elected at annual meeting |
| Class I Director | NA | Frederic Guerard | June 10, 2025 | Elected at annual meeting |
| Class I Director | NA | James McCollum | June 10, 2025 | Elected at annual meeting |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | Election of Kimberlee C. Drapkin and Zach Scheiner as Class III directors to serve until the 2027 annual meeting. | June 10, 2025 | Ensures continuity and stability of the board's Class III members. |
| Board Composition | Election of Frederic Guerard and James McCollum as Class I directors to serve until the 2028 annual meeting. | June 10, 2025 | Ensures continuity and stability of the board's Class I members. |
| Auditor Appointment | Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. | June 10, 2025 | Confirms the company's independent auditor for the current fiscal year, supporting financial transparency and compliance. |
Stakeholder Impact
- Shareholders: The successful election of directors and ratification of the auditor provide clarity and stability regarding the company's governance structure and financial oversight for the upcoming periods.
- Employees: Stable corporate governance can contribute to a more predictable and secure operational environment.
Next Steps
- Class III directors Kimberlee C. Drapkin and Zach Scheiner will hold office until the Company's 2027 annual meeting of stockholders.
- Class I directors Frederic Guerard and James McCollum will hold office until the Company's 2028 annual meeting of stockholders.
- Ernst & Young LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| April 14, 2025 | Record date for the 2025 annual meeting of stockholders. |
| June 10, 2025 | Date of the 2025 annual meeting of stockholders and date of report. |
| December 31, 2025 | Fiscal year end for which Ernst & Young LLP was ratified as the independent registered public accounting firm. |
| 2027 | Expected end of term for elected Class III directors. |
| 2028 | Expected end of term for elected Class I directors. |
Keywords
LENZ Therapeutics, 8-K filing, annual meeting, stockholder vote, director election, corporate governance, auditor ratification, Ernst & Young LLP, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.